P0101 Metformin inhibits cyclin D1 expression in a p53-deficient colon cancer cell line in vitro

Wibowo, Yohanes Cakrapradipta; Mahanani, Melani Ratih; Budiani, Dyah Ratna; Mudigdo, Ambar

doi:10.1016/j.ejca.2015.06.062

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 Metformin memiliki efek anti tumor melalui kerjanya pada MAPK/ LKB1 / TOR yaitu TSC2 dan raptor. 20,21,22,23 Uji invitro sebelumnya menunjukkan efek penghambatan sel kanker terhadap sel WiDr cells untuk sel kanker kolorektal 24 , sel Hep G-2 untuk sel kanker hati 25 , dan sel MCF-7 17…”

Section: Pendahuluanunclassified

Uji Sitotoksik Metformin Hidroklorida Terhadap Sel Kanker Payudara T47d

Rangkuti¹

2019

JKS

View full text Add to dashboard Cite

Abstrak. Latar Belakang. Kanker payudara merupakan penyakit berlebihnya pertumbuhan atau tidak terkendalinya perkembangan sel kanker payudara. Kanker merupakan suatu penyakit yang disebabkan kelainan genetik berupa mutasi DNA yang menyebakan hilangnya kontrol pertumbuhan. Gangguan genetik ini menyebabkan terganggunya siklus sel dan apoptosis. Metformin merupakan suatu antihiperglikemik yang digunakan pada pasien diabetes melitus tipe 2. Penurunan risiko kanker terjadi pada pasien diabetes melitus tipe 2 yang menggunakan metformin. Uji sitotoksik untuk agen anti kanker merupakan uji skrining awal untuk menilai potensi efek anti kanker. Tujuan penelitian ini adalah untuk mengetahui efek sitotoksik metformin hidroklorida terhadap pertumbuhan sel kanker payudara T47D. Metode: Penelitian ini merupakan penelitian eksperimental uji invitro terhadap sel kanker payudara T47D yang dipaparkan metformin HCl konsentrasi 5000; 2500; 1250; 312.5 dan 156,25 μM selama 24 jam. Sebagai pembanding digunakan paclitaxel konsentrasi 1000; 500; 250; 31,25 dan 15,625 nM. Uji sitotoksik menggunakan metode MTT untuk menentukan IC50.Data dianalaisis menggunakan analisa probit. Hasil : IC50 metformin HCl adalah 13457.3 ± 1096,5 μM. IC50 paclitaxel adalah 1577.2 ± 115.3 nM. Efek anti kanker metformin lebih kecil dibanding paclitaxel. Kata Kunci: Metformin HCl, T47D, uji sitotoksik, IC50 Abstract. Breast cancer is a disease in which there is excessive growth or uncontrolled development of breast tissue cells. Cancer is a disease caused by genetic disorders caused by DNA mutations that cause loss of growth control. This genetic disorder affects the cell cycle and cell apoptosis and causes the formation of cancer. Metformin is an antihyperglycemic in type 2 diabetes mellitus patient. The decrease in cancer risk occured in patients with type 2 diabetes mellitus who used metformin. Cytotoxic test for agent anti cancer is screening test to investigate the potency cancer effect of substance. The goal of this study was determining the cytotoxic effect of metformin hydrochloride to T47D breast cancer cell. The method : This sudy was experimental study, invitro test to T47D breast cancer cell using metformin HCl 5000; 2500; 1250; 312.5; and 156.25 μM for 24 hours. Paclitaxel used as postiive control with concentration were 1000; 500; 250; 31,25 and 15,625 nM. Cytotoxic test using MTT method to determine IC50. Data were analyzed using probit analysis using SPSS 22 version. The result of cytotoxic test showed that IC50 metformin HCl was 13457.3 ± 1096,5 μM. While IC50 paclitaxel as control was 1577.2 ± 115.3 nM. The effect of cancer metformin HCl was lower than paclitaxel. Keywords: Metformin HCl, T47D, cytotoxic test, IC50

show abstract

Section: Pendahuluanunclassified

Uji Sitotoksik Metformin Hidroklorida Terhadap Sel Kanker Payudara T47d

Rangkuti¹

2019

JKS

View full text Add to dashboard Cite

show abstract

“…[9] Set the activated AMP-kinase would phosphorylate various substrates that played a role in cell life. [10] It found that the research in in vitro has been done including among several types of cancer cells such as WiDr cells, [11] Hep G-2 cells, [12] MCF-7 cells, [9] MDA-MB-231, [13] and MDA-MB-435 all showing suppression effects of cancer cell growth. This study used T47D cancer cells, ductal type breast cancer cells that express p53 proteins that might be mutated (missense mutation) at residue 194 (in the zinc-binding domain, L2).…”

Section: Introductionmentioning

confidence: 99%

Metformin Inhibits Growth of Breast Cancer Cell T47 through Decreasing Expression of Protein P53, BCL2 and Cyclin D1

et al. 2019

View full text Add to dashboard Cite

Breast cancer is a disease that afflicts women only 0.5 to 1 % are male breast cancers.Breast cancer has several variants and requires a different therapeutic approach, and until now the therapy has not been satisfactory due to the emergence of resistance. Metformin as the main choice drug type 2 diabetes mellitus which is known to have a cytotoxic effect for breast cancer. This study aimed to analyze metformin cytotoxic mechanisms covering the cell cycle , apoptosis, expression of p53, bcl-2 and cyclin D1 T47D cells which exposed to metformin HCl. The study was conducted invitro on T47D breast cancer cells which exposed to metformin concentrations of 1738.2 µg / mL and 3476.4 µg / mL and doxorubicin concentrations of 0.1µg / mL and 0.2µg / mL for 24 hours. Cell cycle testing and apoptosis using the flowsitometry method and expression test of p53 protein, bcl-2 dancycline D1 in T47D cells with immunocytochemistry. Data was analyzed by one way Anova with Bonferroni's advanced test. The results showed that metformin inhibited the G0-G1 phase of the T47D cell cycle, triggered T47D cell apoptosis, significantly reduced p53, bcl-2 and cyclin D1 protein expression (p <0.05). Conclusion of the study, metformin inhibits T47D cells through inhibition of the cell cycle G0-G1 phase, reducing protein expression p53, bcl-2 and cyclin D1.

show abstract

A new contribution for an old drug: Prospect of metformin in colorectal oncotherapy

Jiang¹,

Lu²

2021

J Can Res Ther

View full text Add to dashboard Cite

P0101 Metformin inhibits cyclin D1 expression in a p53-deficient colon cancer cell line in vitro

Cited by 3 publications

References 0 publications

Uji Sitotoksik Metformin Hidroklorida Terhadap Sel Kanker Payudara T47d

Uji Sitotoksik Metformin Hidroklorida Terhadap Sel Kanker Payudara T47d

Metformin Inhibits Growth of Breast Cancer Cell T47 through Decreasing Expression of Protein P53, BCL2 and Cyclin D1

A new contribution for an old drug: Prospect of metformin in colorectal oncotherapy

Contact Info

Product

Resources

About